Last reviewed · How we verify
Human Albumin (colloid)
Human albumin acts as a colloid to expand intravascular volume and maintain oncotic pressure, thereby restoring circulating blood volume and tissue perfusion.
Human albumin acts as a colloid to expand intravascular volume and maintain oncotic pressure, thereby restoring circulating blood volume and tissue perfusion. Used for Hypovolemic shock and acute blood loss, Severe burns, Hypoproteinemia and malnutrition.
At a glance
| Generic name | Human Albumin (colloid) |
|---|---|
| Also known as | Albutein |
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Colloid volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Hematology |
| Phase | FDA-approved |
Mechanism of action
Human albumin is a naturally occurring plasma protein that functions as a volume expander in the intravascular space. It exerts oncotic pressure that draws and retains fluid within blood vessels, preventing fluid shift into the interstitium. This mechanism is used to restore hemodynamic stability in conditions characterized by hypovolemia or severe protein loss.
Approved indications
- Hypovolemic shock and acute blood loss
- Severe burns
- Hypoproteinemia and malnutrition
- Liver cirrhosis with ascites
- Nephrotic syndrome
Common side effects
- Hypervolemia / fluid overload
- Pulmonary edema
- Allergic reaction
- Fever
- Chills
Key clinical trials
- Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study) (PHASE3)
- Guided Fluid-balance Optimization With Mini-fluid chALlenge During Septic Shock (NA)
- Transthoracic Echocardiographic Monitoring of Cardiac Output Effects of Colloid Preload and Crystalloid Coload During Cesarean Delivery Under Spinal Anesthesia (NA)
- CPB Prime Fluid Strategies to Preserve Mcirocirculatory Perfusion (NA)
- Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia (PHASE4)
- Efficacy of 20% Human Albumin in Reducing Pleural Effusion After Cardiopulmonary Bypass (PHASE4)
- The Acute Burn ResUscitation Multicenter Prospective Trial (NA)
- Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |